- Nordic Pharma, Inc. launches an authorized generic version of Maxitrol® through a partnership with Harrow (HROW, Financial).
- The generic Maxitrol® targets bacterial eye infections, leveraging a U.S. market opportunity valued at $20.8 million annually as of January 2025.
- This strategic move adds a cost-effective option to Nordic Pharma's growing portfolio in the pharmaceutical sector.
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has collaborated with Harrow (HROW) to introduce an authorized generic version of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension). This venture is aimed at providing an affordable treatment for bacterial eye infections within the U.S. market.
According to January 2025 IQVIA data, Maxitrol® and its generic versions generated annual sales of $20.8 million in the United States. This highlights the significant market potential that Nordic Pharma and Harrow aim to capture through their new offering.
The release of this authorized generic aligns with Nordic Pharma's strategy to expand its portfolio in specialized areas such as Eye Care, Rheumatology, and Women's Health. Thomas Sammler, VP of Commercial Operations, emphasized the importance of this launch, stating it is the result of extensive efforts to provide patients with an affordable prescription option.
Harrow (HROW, Financial), listed on Nasdaq, is a renowned eyecare pharmaceutical company focusing on making innovative ophthalmic products widely accessible and affordable across North America. This partnership reinforces both companies' commitment to enhancing healthcare quality and access.
